Sheet 1 of 2

FORM PTO-1449

TENT AND TRADEMARK OFFICE NAPRO-4.

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

TECH CENTER

SERIAL NO. 09/818,875

Eric B. Kmiec et al.

FILING DATE March 27, 2001 **GROUP** 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Our	5,565,350	10/15/96	Kmiec	435	172.3	
	5,731,181	3/24/98	Kmiec	435	172.3	
	5,912,340	6/15/99	Kutyavin	536	24.5	
	6,004,804	12/21/99	Kumar	435	320.1	
gulf _	6,271,360	8/7/01	Metz	536	23.1	
V						

FOREIGN PATENT DOCUMENTS

		FUREIGN P	ATENT DOCOR	/IEIN/IS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
$\mathcal{J}U$	WO 99/14226	3/25/99	PCT				
	WO 00/56748	9/28/00	PCT				
	WO 00/66604	11/9/00	PCT				
0							
			1				
		.^					
						,	
						-	
			·				

EXAMINER

DATE CONSIDERED

EXAMINED: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

and .





FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OF ICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.
Napro-4

APPLICANT
Eric B. Kmiec et al.

FILING DATE
March 27, 2001

SERIAL NO.
09/818,875

GROUP
1635

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	
	Alexeev & Yoon, "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," Nature Biotech. 16:1343-1346 (1998)
	Campbell et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," New Biologist 1:223-227 (1989)
	Chan & Glazer, "Triplex DNA: fundamentals, advances, and potential applications for gene therapy," <u>J. Mol. Med.</u> 75:267-282 (1997)
	Chan et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," <u>J. Biol. Chem.</u> 274:11541-11548 (1999)
	Cole-Strauss et al., "Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide," Science 273:1386-1389 (1996)
	Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," Nat. Biotechnol. 17:989-993 (1999)
	Gamper et al., "The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts," <u>Nucleic Acids Res.</u> 28:4332-4339 (2000)
	Igoucheva et al., "Targeted gene correction by small single-stranded oligonucleotides in mammalian cells," Gene Therapy 8:391-399 (2001)
	Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," Proc. Natl. Acad. Sci. USA 96:10349-10354 (1999)
	Kunzelmann et al., "Gene targeting of CFTR DNA in CF epithelial cells," Gene Ther. 3:859-867 (1996)
	Moerschell et al., "Transformation of yeast with synthetic oligonucleotides," Proc. Natl. Acad. Sci. USA 85:524-528 (1988)
	Rando et al., "Rescue of dystrophin expression in <i>mdx</i> mouse muscle by RNA/DNA oligonucleotides," Proc. Natl. Acad. Sci. USA 97:5363-5368 (2000)
	Vasquez et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," Nucl. Acids Res. 27:1176-1181 (1999)
	Vasquez et al., "Specific mutations induced by triplex-forming oligonucleotides in mice," <u>Science</u> 290:530-532 (2000)
	Yamamoto et al., "Strand-specificity in the transformation of yeast with synthetic oligonucleotides," <u>Genetics</u> 131:811-819 (1992)
	Yanez & Porter, "Therapeutic gene targeting," Gene Therapy 5:149-159 (1998)
	Xu et al., "Activation of human γ -globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ -globin gene 5' flanking region," Gene 242:219-228 (2000)

EXAMINER

DATE CONSIDERED

5-15-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.